Abstract: A composition and method for enhancing transdermal penetration of a basic drug are described. The composition comprises a matrix patch comprising an effective amount of a basic drug, preferably having a pK.sub.a of about 8.0 or greater, an effective amount of penetration enhancer consisting essentially of triacetin, and a polymer later preferably comprising a pressure-sensitive adhesive. A preferred basic drug is oxybutynin and acid addition salts thereof. The method for enhancing transdermal penetration comprises applying the matrix patch to a selected area of skin.

Abstract: The subject invention encompasses a transdermally or transmucosally administrable composition for the treatment or nicotine craving or smoking withdrawal symptoms comprising nicotine and caffeine or caffeine equivalent.

Abstract: A method and article are disclosed for topical application of tea, such as orange pekoe or black, to improve the appearance of spider veins and varicose veins. A method and article are also disclosed for topical application of tea to improve circulation in the extremities.

Abstract: The present invention provides a pharmaceutical composition for the transdermal systemic administration of an active agent characterized in that the active agent is bopindolol or methysergide. Also the present invention provides a pharmaceutical composition for the transdermal systemic administration of a pharmacologically active agent characterized in that it contains bopindolol, tizanidine, clemastine, ketotifen or methysergide as active agent in a reservoir comprising a hydrophilic polymer. Furthermore a pharmaceutical composition for the transdermal systemic administration of pharmacologically active agents characterized in that the pharmacologically active agent is in a reservoir comprising a polyacrylate polymer containing cationic ester groups.

Abstract: An improved wound dressing having an adhesive layer (26, 426) containing one or more hydrocolloids dispersed in a viscous elastomer, a flexible water-impervious backing layer (22, 322, 422) on one side of the adhesive layer, and a removable release layer (28, 328, 428) on the adhesive layer's opposite side. The dressing includes a body portion (36) with a stair-like outer contour merging with a peripheral flange (38, 238, 338, 438) of reduced thickness. The flange (38, 238, 338, 438) is required to have a width of at least 5 mm. and the thickness of the adhesive layer of that flange is no greater than 0.5 mm., for purposes of overcoming prior problems of adhesive flow, fluid channeling, leakage, and unintentional detachment.

Abstract: A feed composition containing fumaric acid or a salt thereof, a concentrate feed and, if necessary, a roughage is fed to ruminants. The ratio of the concentrate to the roughage is about 90-10/10-90 (% by weight). When fumaric acid or a salt thereof in a granular form such as mean particle diameter of not less than 75 mesh is added to a ration, the proportion of acetic acid and propionic acid among volatile fatty acids (VFA) in the ruminant animal is increased for a sustained time to enhance the efficiency of milk and meat production and improve the quality of meat. The proportion of fumaric acid or a salt thereof is about 0.1 to 10% by weight. The addition of fumaric acid or a salt thereof helps to suppress flatulence which tends to occur on feeding with concentrates.

Abstract: A transdermal drug delivery device involving a backing bearing at least one adhesive layer of an acrylate copolymer and a therapeutically effective amount of (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole. The device optionally further involves (i) a second adhesive layer of an acrylate copolymer and optionally a therapeutically effective amount of (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole, and (ii) a membrane intermediate the first and second adhesive layers.

Abstract: This invention is concerned with a new transdermal matrix system for the percutaneous administration of a hormone, said matrix system, which has a support and a self-adhesive matrix, comprising a matrix containing:(a) 20 to 42 parts by weight of a poly(styrene-isoprene-styrene) triblock copolymer,(b) 35 to 55 parts by weight of a tackifying resin.(c) 5 to 25 parts by weight of a plasticizing agent selected from the group consisting of oleic alcohol, peglicol 5-oleate, propyleneglycol laurate or a polypropoxyl ether of cetyl alcohol,(d) 5 to 15 parts by weight of at least one compound selected from the group consisting of:crotamiton, andN-substituted 2-pyrrolidones of formula I, ##STR1## wherein R represents a (C.sub.1 -C.sub.15)-alkyl, cyclohexyl or 2-hydroxyethyl group,(e) 0,01 to 1 part by weight of a stabilizing agent and,(f) 0,1 to 5 parts by weight of a hormone selected from the group consisting of oestrogen components, progestogen components and mixtures thereof.

Abstract: Polysiloxane emulsions, useful for treating tissues to improve tactile characteristics, are effectively preserved with at least about 0.1 weight percent of methyl p-hydroxybenzoate. Preferably the preservative further contains one or more p-hydroxybenzoate esters and 2-phenoxyethanol and/or ethylenediaminetetraacetic acid.

Abstract: Hot-melt silicone pressure sensitive adhesive compositions containing organic waxes, methods of using the compositions and devices made using the compositions are disclosed. The hot-melt silicone pressure sensitive adhesive compositions include a mixture of (i) a silicate resin, (ii) a silicone fluid, and (iii) an organic wax having a melting point of between 30.degree. C. and 150.degree. C. The organic wax decreases dynamic viscosity of the adhesive at temperatures equal to or below about 200.degree. C.

Abstract: A drug flux enhancer-tolerant pressure sensitive adhesive composition is provided comprised of a mixture of (1) a percutaneous penetration enhancer to increase permeability of skin to transdermally administered pharmacologically active agents and (2) a macromer reinforced base polymer, said base polymer comprising a phase separated graft copolymer composition comprised of copolymerized monomers A and B to form a backbone polymer having polymeric moieties grafted thereto, wherein monomer A is a monomeric acrylic or methacrylic ester of a non-tertiary alcohol having from 1 to 14 carbon atoms, with the average number of carbon atoms being in the range of about 4 to 12, and a monomer B is a polar monomer which is copolymerizable with monomer A.

Abstract: Disclosed is the feed or feed additive granular agent containing a physiologically active substance and a coating layer having a laminar structure in which the tabular crystals are arranged in a laminated state. The coating layer comprises (a) one or more substances selected from the group consisting of a specific fatty acid or ester thereof, a specific animal or vegetable fat and fatty oil which may be hardened by hydrogenation, and a specific wax, and (b) tabular crystals of a substance which is sparingly water-soluble under a neutral condition but is readily water-soluble under an acidic condition and which has an average particle size of 5 to 30 .mu.m, wherein said coating layer is present in a coating ratio of 5% by weight or more and 50% by weight or less, wherein said first coating material and said second coating material are in a proportion of 3:2 to 1:3 by weight, and process for producing the same.

Abstract: Disclosed is a process for producing a composition for ruminants, which is characterized in that a nucleus containing a physiologically active substance is coated with a coating material prepared by suspending in water (i) an emulsion comprising water and at least one hydrophobic substance hardly soluble in water and (ii) a slurry containing at least one polymer soluble in water of pH 5.0 or below and insoluble in water of pH over 5.0 In the process, an aqueous suspension is used for coating instead of a meterial dissolved in an organic solvent.

Abstract: A drug capsule comprises a sleeve forming a side wall of the capsule and having first and second end caps which close the opened ends of the sleeve. The end faces of the end caps are frangible so that they can be ruptured by the open ends of the sleeve by causing the end caps to be displaced along the sleeve towards one another to open the capsule. A dispenser is formed from the combination of the capsule and a pair of elements, each element being adapted to receive a respective one of the end caps so that the capsule interconnects the elements, whereby the capsule can be opened by moving the elements towards one another. One of the elements provides a mouth piece and the other element provides an air flow passageway provided with a turbine to induce turbulence in the air flow through the capsule. The drug capsule and dispenser are primarily intended for administering powdered drugs by inhalation.

Abstract: A sustained release capsule adapted to be inserted into the rumen of a ruminant animal and means for retention of the capsule in the rumen.

Abstract: Dosage forms for the transdermal administration of apomorphine are described. The dosage forms are water-soluble gel compositions that contain apomorphine, optionally together with a permeation enhancer, or transdermal patches.

Abstract: Transdermal absorption dosage units have been developed which comprise a backing layer and an adjoining polyacrylate adhesive polymer layer in which at least minimum effective daily doses of one or more steroidal hormones are microdispersed. Presently preferred is use of the natural estrogen, 17-beta-estradiol, or ethinyl estradiol or combinations thereof together with an amount of a natural progestogen or a progestin to minimize any potential side effects. The units use bioacceptable polyacrylate adhesive polymer in making the adhesive polymer layer which has a minor percentage of vinyl acetate polymer units effective in providing improved transdermal absorption of the microdispersed steroidal hormone. An effective amount of vinyl acetate units up to about 5 percent has been found suitable. The invention also provides a process for transdermal administration of one or more steroidal hormones using the novel dosage units provided.

Abstract: The present invention relates to a pelletization-resistant rumen bypass formulation of a feed additive resistant to pelletization by applying a reinforcement measure resisting to a mechanical stress during the pelletization and humidification and heating at steaming, etc. to a rumen bypass formulation formed of biologically active principles and protective matrices and a feed pellet for ruminants containing said pelletization-resistant rumen bypass formulation therein. More particularly, the present invention relates to a pelletization-resistant rumen bypass formulation prepared by including one or more rumen bypass formulations formed of biologically active principles and protective matrices in the moldings of various types of macromolecules described above (pelletization-resistant protective matrices) having a shape retaining property during a process of pelletization, and a feed pellet for ruminants applying the same.

Abstract: The present invention is directed to a sticky composition for medical use comprising a tackifier resin and an oxyalkylene polymer having a silicon-containing group which can be crosslinked by forming a siloxane bond, wherein silicon atom thereof is bound with a hydroxyl group or hydrolytic group, and to a transdermal drug delivery preparation incorporating said sticky composition as a drug carrier. The sticky composition of the present invention possesses excellent adhesive properties, very low skin irritancy and good compatibility with the site of plastering and thus perform as a very safe and effective medical adhesive. The transdermal drug delivery preparation of the present invention offers excellent drug release from the sticky composition.

Abstract: Films based on copolymers, their applications in transdermal systems and their processes of preparation. The said films consist of a hydrophobic polymer of ethylene/vinyl acetate (EVA) type containing at least one active principle and composed of 15 to 50% of hydrophilic inclusions formed from at least one hydrophilic monomer chosen from the group which comprises acrylamide, methylolacrylamide, diacetone acrylamide, maleic acid, acrylic acid, fumaric acid, itaconic acid, propylene glycol acrylate, ethylene glycol methacrylate, methacrylamide, methacrylic acid, propylene glycol methacrylate, hydroxyethyl methacrylate, dimethylaminoethyl methacrylate, N-vinylpyrrolidone, vinylacetic acid or vinylsulphonic acids.